[Experimental study on immunochemotherapy using schizophyllan].
Immunochemotherapy with schizophyllan (SPG) combined with chemotherapeutic agents was evaluated in two syngeneic tumor-C3H/He mouse systems. The administration of SPG alone caused a significant growth inhibition of MM 46 mammary carcinoma, the highest therapeutic effect being obtained by SPG given at the advanced stage of tumors. When combined with neocarzinostatin given 7-times every other day the simultaneous administration of SPG produced an optimal response to that therapy. In X-5563 plasmacytoma, SPG alone was ineffective. However, when combined with mitomycin C given with 1 to 5-days interval, the concurrent administration of SPG prolonged significantly the life-span of the tumor-bearing mice. These results indicated that the simultaneous administration of SPG and antitumor drugs may be a useful application method for immunochemotherapy of experimental tumors.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009374:Neoplasms, Experimental / Q000628:therapy*; D010954:Plasmacytoma / Q000628:therapy; D012566:Sizofiran / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000187:drug effects; D009353:Zinostatin / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D006025:Glycosaminoglycans; D008937:Mitomycins; D016685:Mitomycin; D012566:Sizofiran; D009353:Zinostatin